Evidence map›Paper›PMID 37790613›Full record

ArticlePeerJ2023

Fluorofenidone alleviates liver fibrosis by inhibiting hepatic stellate cell autophagy

Xiongqun Peng, Huixiang Yang, Lijian Tao, Jingni Xiao, Ya Zeng, Yueming Shen, Xueke Yu, Fei Zhu, Jiao Qin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Xiongqun PengDepartment of Gastroenterology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Huixiang YangDepartment of Gastroenterology, Xiangya Hospital, Central South University, Changsha, China.
Lijian TaoDepartment of Nephropathy, Xiangya Hospital, Central South University, Changsha, China.
Jingni XiaoDepartment of Nephrology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Ya ZengDepartment of Gastroenterology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Yueming ShenDepartment of Gastroenterology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Xueke YuDepartment of Gastroenterology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Fei ZhuDepartment of General Surgery, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Jiao QinDepartment of Nephrology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
University of South China · CNChangsha Central Hospital · CNCentral South University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Liver fibrosis is a key stage in the progression of various chronic liver diseases to cirrhosis and liver cancer, but at present, there is no effective treatment. This study investigated the therapeutic effect of the new antifibrotic drug fluorofenidone (AKF-PD) on liver fibrosis and its related mechanism, providing implications for liver cancer. Materials and Methods: The effects of AKF-PD on hepatic stellate cell (HSC) autophagy and extracellular matrix (ECM) expression were assessed in a carbon tetrachloride (CCl Results: AKF-PD attenuated liver injury and ECM deposition in the CCl Conclusions: AKF-PD alleviates liver fibrosis by inhibiting HSC autophagy

Indexed as

Hepatic Stellate CellsLiver NeoplasmsAnimalsAutophagyBeclin-1FibrosisLiver CirrhosisPyridonesRatsSignal TransductionTransforming Growth Factor beta15-methyl-1-(3-fluorophenyl)-2-(1H)-pyridoneBeclin-1PyridonesTransforming Growth Factor beta1AKF-PDAutophagyHepatic stellate cellLiver fibrosisTGF-β1/Smad pathway

Identifiers

PMID37790613
PMCPMC10542821
OpenAlexW4387119391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.